Isoniazid-resistant tuberculosis treatment with first-line drugs-Author reply

Affiliations

Comment

Dick Menzies. Lancet Infect Dis. 2017 Mar.

. 2017 Mar;17(3):260.

doi: 10.1016/S1473-3099(17)30077-4. Epub 2017 Feb 23.

¹ Montreal Chest Institute, McGill University, Montreal, Canada H3H 2R9. Electronic address: dick.menzies@mcgill.ca.

No abstract available

Comment on

Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis.
Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Gegia M, et al. Lancet Infect Dis. 2017 Feb;17(2):223-234. doi: 10.1016/S1473-3099(16)30407-8. Epub 2016 Nov 17. Lancet Infect Dis. 2017. PMID: 27865891
Isoniazid-resistant tuberculosis treatment with first-line drugs.
Andre E, Martin A. Andre E, et al. Lancet Infect Dis. 2017 Mar;17(3):258-259. doi: 10.1016/S1473-3099(17)30075-0. Epub 2017 Feb 23. Lancet Infect Dis. 2017. PMID: 28244383 No abstract available.
Isoniazid-resistant tuberculosis treatment with first-line drugs.
Chien JY, Wang JY. Chien JY, et al. Lancet Infect Dis. 2017 Mar;17(3):259-260. doi: 10.1016/S1473-3099(17)30076-2. Epub 2017 Feb 23. Lancet Infect Dis. 2017. PMID: 28244385 No abstract available.